Skip to main content
. 2009 May 12;17(8):1387–1394. doi: 10.1038/mt.2009.90

Figure 2.

Figure 2

Combined treatment of OGX-427 with irradiation enhances the regression of SQ20B xenografted tumors. Mice bearing SQ20B tumors were randomly selected for treatment with PBS, 10 mg/kg of MS-control or OGX-427 injected once daily for 5 consecutive days (week 1) then three times per week for 5 weeks, associated or not with local tumor irradiation for a total dose of 10 or 30 Gy delivered at a daily dose of 2 Gy. (a) Tumor evolution after treatment with PBS, MS-control or OGX-427 oligonucleotides associated or not with 10 Gy radiation (week 2, experiment I). (b) Tumor evolution after treatment with PBS associated or not with 30 Gy irradiation, and OGX-427 plus 30 Gy (weeks 2, 3, and 4, experiment II). Tumor volume was measured once weekly and results were expressed as mean ± SD relative to that measured at the beginning of treatment. (c) Tumor specimen photos representative of each group of mice at the end of the treatment (experiment II). (d) Immunoblot analysis of Hsp27, Hsp70, and Hsp90 proteins in SQ20B xenografted tumors at the end of treatment for all experimental groups (two different tumors from each group). Protein (2 µg) was loaded on the gels. GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; Hsp, heat shock protein; PBS, phosphate-buffered saline.